JP7863101B2 - 医学的療法のための、ネオ基質を分解する三環式化合物 - Google Patents

医学的療法のための、ネオ基質を分解する三環式化合物

Info

Publication number
JP7863101B2
JP7863101B2 JP2023523013A JP2023523013A JP7863101B2 JP 7863101 B2 JP7863101 B2 JP 7863101B2 JP 2023523013 A JP2023523013 A JP 2023523013A JP 2023523013 A JP2023523013 A JP 2023523013A JP 7863101 B2 JP7863101 B2 JP 7863101B2
Authority
JP
Japan
Prior art keywords
particular embodiment
alkyl
formula
ring
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023523013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545509A (ja
JP2023545509A5 (cg-RX-API-DMAC10.html
Inventor
クリストファー ジー. ナスヴェシュク
コリー ドン アンダーソン
ジェームズ エー. ヘンダーソン
ビクトリア ガルザ
ヤンケ リャン
モーゼ ムースタキム
モーガン ヴェルツェル オーシェア
Original Assignee
シーフォー セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーフォー セラピューティクス, インコーポレイテッド filed Critical シーフォー セラピューティクス, インコーポレイテッド
Publication of JP2023545509A publication Critical patent/JP2023545509A/ja
Publication of JP2023545509A5 publication Critical patent/JP2023545509A5/ja
Application granted granted Critical
Publication of JP7863101B2 publication Critical patent/JP7863101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C07D209/92—Naphthostyrils
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023523013A 2020-10-14 2021-10-14 医学的療法のための、ネオ基質を分解する三環式化合物 Active JP7863101B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091894P 2020-10-14 2020-10-14
US63/091,894 2020-10-14
PCT/US2021/055104 WO2022081927A1 (en) 2020-10-14 2021-10-14 Tricyclic compounds to degrade neosubstrates for medical therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026079082A Division JP2026133474A (ja) 2020-10-14 2026-05-08 医学的療法のための、ネオ基質を分解する三環式化合物

Publications (3)

Publication Number Publication Date
JP2023545509A JP2023545509A (ja) 2023-10-30
JP2023545509A5 JP2023545509A5 (cg-RX-API-DMAC10.html) 2024-10-22
JP7863101B2 true JP7863101B2 (ja) 2026-05-20

Family

ID=81208653

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523013A Active JP7863101B2 (ja) 2020-10-14 2021-10-14 医学的療法のための、ネオ基質を分解する三環式化合物

Country Status (10)

Country Link
US (1) US20240018118A1 (cg-RX-API-DMAC10.html)
EP (1) EP4228624A4 (cg-RX-API-DMAC10.html)
JP (1) JP7863101B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230107807A (cg-RX-API-DMAC10.html)
CN (2) CN122277521A (cg-RX-API-DMAC10.html)
AU (1) AU2021360596A1 (cg-RX-API-DMAC10.html)
CA (1) CA3194351A1 (cg-RX-API-DMAC10.html)
IL (1) IL302036A (cg-RX-API-DMAC10.html)
MX (1) MX2023004369A (cg-RX-API-DMAC10.html)
WO (1) WO2022081927A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
JP7863100B2 (ja) * 2020-10-14 2026-05-20 シーフォー セラピューティクス, インコーポレイテッド Ikzf2又はikzf4を分解する三環式リガンド
JP7807110B2 (ja) * 2021-08-27 2026-01-27 ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド イソインドリノン化合物およびその使用
JP2025501056A (ja) 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
JP2025531869A (ja) * 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド CK1αおよびDUAL CK1α/GSPT1分解化合物
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
KR20250079173A (ko) 2022-10-03 2025-06-04 고리츠다이가쿠호진 요코하마시리츠다이가쿠 이환성 구조를 갖는 이미다조피리딘 유도체
WO2024096753A1 (en) 2022-11-02 2024-05-10 Captor Therapeutics S.A. Nek7 degraders and methods of use thereof
WO2024153246A1 (zh) * 2023-01-20 2024-07-25 海南先声再明医药股份有限公司 取代的三环化合物及其应用
CN120569372A (zh) 2023-01-24 2025-08-29 第一三共株式会社 经取代的苯化合物
CN117903192A (zh) * 2023-03-12 2024-04-19 上海相辉医药科技有限公司 一种3-甲氧基异喹啉化合物中间体的制备方法
WO2024259303A1 (en) * 2023-06-16 2024-12-19 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as cereblon ligands and uses thereof
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 3-苯基丙基胺衍生物
WO2025162410A1 (zh) * 2024-01-31 2025-08-07 微境生物医药科技(上海)有限公司 新型蛋白降解剂及抗体-蛋白降解剂偶联物
CN121620373A (zh) * 2024-07-26 2026-03-06 上海超阳药业有限公司 苯并吲哚衍生物的药物组合物、制备方法及用途
TW202615052A (zh) * 2024-08-27 2026-04-16 日商第一三共股份有限公司 多環性化合物
WO2026064643A1 (en) * 2024-09-20 2026-03-26 Plexium, Inc. Compounds, compositions, and methods of use thereof
WO2026065268A1 (en) * 2024-09-29 2026-04-02 Biofront Ltd Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241274A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2023538520A (ja) 2020-08-07 2023-09-08 シーフォー セラピューティクス, インコーポレイテッド Ikaros又はaiolosによって媒介される障害に対する有利な治療法
JP2023545507A (ja) 2020-10-14 2023-10-30 シーフォー セラピューティクス, インコーポレイテッド 標的化タンパク質を分解する三環式ヘテロ二官能性化合物
JP2023545508A (ja) 2020-10-14 2023-10-30 シーフォー セラピューティクス, インコーポレイテッド Ikzf2又はikzf4を分解する三環式リガンド
JP7692362B2 (ja) 2019-04-12 2025-06-13 シーフォー セラピューティクス, インコーポレイテッド Ikaros及びAiolosの三環式分解誘導薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517766A (ja) * 2003-09-24 2007-07-05 コンビナトアールエックス インコーポレーティッド 薬物の組み合わせを投与するための治療法
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
CN111662226B (zh) * 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
IL319363A (en) * 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
US10738056B2 (en) * 2017-09-15 2020-08-11 Aduro Biotech Inc. Pyrazolopyrimidinone compounds and uses thereof
JP2021512153A (ja) * 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
US12030892B2 (en) * 2018-06-29 2024-07-09 Dana-Farber Cancer Institute, Inc. CRBN modulators
CN116194453A (zh) * 2019-12-20 2023-05-30 卡里科生命科学有限责任公司 蛋白质酪氨酸磷酸酶降解剂及其使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241274A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7692362B2 (ja) 2019-04-12 2025-06-13 シーフォー セラピューティクス, インコーポレイテッド Ikaros及びAiolosの三環式分解誘導薬
JP2023538520A (ja) 2020-08-07 2023-09-08 シーフォー セラピューティクス, インコーポレイテッド Ikaros又はaiolosによって媒介される障害に対する有利な治療法
JP2023545507A (ja) 2020-10-14 2023-10-30 シーフォー セラピューティクス, インコーポレイテッド 標的化タンパク質を分解する三環式ヘテロ二官能性化合物
JP2023545508A (ja) 2020-10-14 2023-10-30 シーフォー セラピューティクス, インコーポレイテッド Ikzf2又はikzf4を分解する三環式リガンド

Also Published As

Publication number Publication date
AU2021360596A1 (en) 2023-06-08
JP2023545509A (ja) 2023-10-30
WO2022081927A1 (en) 2022-04-21
EP4228624A4 (en) 2025-04-23
CN122277521A (zh) 2026-06-26
CA3194351A1 (en) 2022-04-21
EP4228624A1 (en) 2023-08-23
CN116457339A (zh) 2023-07-18
US20240018118A1 (en) 2024-01-18
IL302036A (en) 2023-06-01
KR20230107807A (ko) 2023-07-18
AU2021360596A9 (en) 2024-02-08
MX2023004369A (es) 2023-07-06

Similar Documents

Publication Publication Date Title
US20240018118A1 (en) Tricyclic compounds to degrade neosubstrates for medical therapy
JP7863100B2 (ja) Ikzf2又はikzf4を分解する三環式リガンド
US20230372496A1 (en) Tricyclic heterobifunctional compounds for degradation of targeted proteins
EP4735438A2 (en) Heterobifunctional compounds for the degradation of kras
KR20230172548A (ko) Mek 억제제 및 이의 용도
TWI884914B (zh) 喋啶酮化合物及其用途
WO2017223243A1 (en) Cxcr4 inhibitors and uses thereof
JP2026076261A (ja) 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
CA3027495A1 (en) Cxcr4 inhibitors and uses thereof
WO2020206034A1 (en) Cell cycle inhibiting compounds for the treatment of medical disorders
RS63281B1 (sr) Antiproliferativna jedinjenja i njihova upotreba
WO2022051567A1 (en) Substituted pyrido[2,3-b]pyrazinones and reuated compounds and their use in treating medicau conditions
TW202615048A (zh) Ras抑制劑
JP2025540906A (ja) Ret-lddタンパク質阻害剤
HK40050670A (en) Substituted piperidines as cxcr4-inhibitors
EA047483B1 (ru) Ингибиторы tead и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260508

R150 Certificate of patent or registration of utility model

Ref document number: 7863101

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150